Lipoprotein(a) in interventional cardiology: identifying patients at highest risk of recurrent cardiovascular events through early recognition - a case based review.
Mick P L RenkensCasper F CoerkampLars S WitteShabiga SivanesanNick S NurmohamedMarit WesterterpPatrick SerruysYoshinobu OnumaMaik J GrundekenDeborah N KalkmanMarcel BeijkMarije M VisJosé P S HenriquesRonak DelewiErik StroesJoanna J WykrzykowskaRobbert J de WinterBimmer E P M ClaessenPublished in: Expert review of cardiovascular therapy (2024)
We highlighted the importance of routine Lp(a) measurement in identifying patients at high risk for atherosclerosis, necessitating potent risk mitigation. Measuring Lp(a) helps clinicians identify which patients are at highest residual risk, who require potent pharmacological treatment and special attention during catheter interventions. As noninvasive and advanced intravascular imaging modalities evolve, future catheterization laboratories will integrate advanced imaging, diagnostics, and treatment, facilitating tailored patient care. Knowing Lp(a) levels is crucial in this context. While Lp(a)-lowering drugs are currently investigated in clinical trials, it is of paramount importance to know Lp(a) levels and strive toward aggressive management of other modifiable risk factors in patients with elevated Lp(a) and established symptomatic CAD being diagnosed or treated in catheterization laboratories.
Keyphrases
- cardiovascular events
- end stage renal disease
- clinical trial
- newly diagnosed
- risk factors
- coronary artery disease
- high resolution
- cardiovascular disease
- prognostic factors
- peritoneal dialysis
- coronary artery
- patient reported outcomes
- working memory
- cardiac surgery
- photodynamic therapy
- mass spectrometry
- patient reported
- clinical practice
- phase ii
- phase iii